Ensign Peak Advisors
ADVM

Ensign Peak Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Ensign Peak Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-9,307
Closed -$959K – 1855
2020
Q3 		$959K Buy
+9,307
New +$1.39M ﹤0.01% 1326

Other funds holding ADVM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Ensign Peak Advisors's ADVM Position: Q4 2020 in Review

Ensign Peak Advisors sold out of Adverum Biotechnologies (ADVM) in Q4 2020, closing a stake of 9,307 shares — an estimated $959K sold.

Ensign Peak Advisors first reported a position in ADVM in Q3 2020 and held it in 1 quarter. The position peaked at $959K in Q3 2020. 155 funds tracked by Wall St. Rank hold ADVM as of Q4 2020.

  • Ensign Peak Advisors reported no remaining Adverum Biotechnologies position as of Q4 2020 after selling out during the quarter.
  • Ensign Peak Advisors sold 9,307 Adverum Biotechnologies shares in Q4 2020, an estimated $959K.
  • Ensign Peak Advisors first reported a position in Adverum Biotechnologies in Q3 2020 and held it in 1 quarter.
  • Ensign Peak Advisors's Adverum Biotechnologies position peaked at $959K in Q3 2020.
  • 155 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2020.

Based on Ensign Peak Advisors's 13F filing for Q4 2020, filed 12 Feb 2021.